GENFIT: General Meeting vote results

- All resolutions were adopted, in accordance with the Management Board’s recommendations
- Mr. Xavier Blain (CIC Finance) appointed new member of the Supervisory Board

Lille (France), Cambridge (Massachusetts, United States), July 2nd, 2009 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces the voting results of its Annual Ordinary General Meeting held on June 26th, 2009 in Lille (France). During this meeting, the annual reports as well as the corporate and consolidated financial statements for 2008 were unanimously approved.

A total of 19,381,412 votes were recorded out of 19,840,256 voting rights, thus representing a quorum of 97.7%.

The voting results on the resolutions proposed by the Management Board are the following:

FIRST RESOLUTION:
Approval of annual reports and financial statements for the year ending December 31, 2008: resolution adopted unanimously.

SECOND RESOLUTION:
Approval of reports and consolidated financial statements for the year ending December 31, 2008: resolution adopted unanimously.

THIRD RESOLUTION:
Income allocation for the year ending December 31, 2008: resolution adopted unanimously.

FOURTH RESOLUTION:
Approval of regulated agreements covered by the special Auditor’s report: resolution adopted unanimously.

FIFTH RESOLUTION:
Reading of the special report of the Management Board on subscribing options for shares in accordance with Article L. 225-184 of the Commercial Law: resolution adopted unanimously.

SIXTH RESOLUTION:
Reading of the special report of the Management Board on the award of bonus shares in accordance with Article L. 225-197-4 of the Commercial Law: resolution adopted unanimously.

SEVENTH RESOLUTION:
Reading of the complementary report of the Management Board on the delegation of powers and authority granted to it by the General Assembly in accordance with Articles L. 225-129-1 and following of the Commercial Law: resolution adopted unanimously.

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English languages. In the event of any differences between the two texts, the French language version shall supersede.
EIGHTH RESOLUTION:
Appointment of a new member of the Supervisory Board to replace a resigning member: resolution adopted unanimously.

The General Meeting took note of the resignation of Mr. Laurent Lannoo from membership of the Supervisory Board with effect from the end of the meeting, resignation motivated by his appointment as Genfit’s Corporate Secretary in July 2008, and decided to appoint Mr. Xavier Blain as permanent representative of the CIC Finance Company.

The CIC Finance Company and Mr. Xavier Blain indicated that they accept the tasks that are conferred to them and that they meet all the legal and regulatory requirements.

Mr. Xavier Blain, Member of the Management Board of the CIC Finance Company, a private equity society handling 700 M€ investments in medium-sized enterprises, declared: «The CIC Finance Company is very pleased to join the Supervisory Board of Genfit, thus strengthening his position among companies belonging to the Health industry. »

«I am delighted to welcome the CIC Finance Company to our Board at a time which Genfit is active in organizing major strategic agreements regarding both the development of its drug candidates and from a financial point of view» announced Jean-François Mouney, Chairman of the Management Board.

NINTH RESOLUTION:
Allocation of attendance fees: resolution adopted by a majority. By 16,016,612 votes in favor and 1,880,000 votes against and 1,484,800 abstention votes, translating a majority of 82.64% participating votes.

TENTH RESOLUTION:
Formality powers: resolution adopted unanimously.

About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neurodegenerative disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, Alzheimer’s...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health concerns and their unmet medical needs. GENFIT’s proprietary research programs and its partnerships with leading pharmaceutical companies, including SANOFI-AVENTIS, SOLVAY GROUP, PIERRE FABRE, and SERVIER, have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and two other compounds, respectively in partnership with SANOFI-AVENTIS (AVE0897) and SOLVAY (SLV341), are in the advanced stages of Phase I. With facilities in Lille, France, and Cambridge, MA (USA), the Company has about 130 employees, including over 100 scientists. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:
GENFIT
Jean-François Mouney – Chairman of the Management Board
+33 (0)3 20 16 40 00

MILESTONES – Press Relations
Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 - milestones@milestones-fr.com